NEW YORK, NY, USA & MAINZ, Germany I, 2024 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced ...
PARIS, France I, 2024 I Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has conditionally approved Iqirvo® ...
INCHEON, South Korea and CAMBRIDGE, MA, USA I September 20, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...
SAN DIEGO, CA, USA & EDMONTON, Canada I 19, 2024 I Aegis Life, Inc. (Aegis) and its partner Entos® Pharmaceuticals (Entos), announced today that ...
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial. CD-001, the ...
LONDON, UK and CAMBRIDGE, MA, USA I September 19, 2024 I Beacon Therapeutics Holdings Limited ('Beacon' or 'the Company'), a leading ophthalmic gene therapy ...
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 ...
SILVER SPRING, MD, USA I September 20, 2024 I Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).
COPENHAGEN, Denmark I 19, 2024 I Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for ...
EMERYVILLE, CA, USA I September 18, 2024 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company ...
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback